Connect your AI

MiniMed Group MMED Research and development expense

Research and development expense at other companies

ON SemiconductorON

$144.3M-12.1%

TG TherapeuticsTGTX

$43.52M+1.1%

Corvex MOVE

$899K+12.4%

Monolithic Power SystemsMPWR

$100.57M+9.0%

Boston ScientificBSX

$516M+16.5%

Teradyne, Inc.TER

$135.56M+14.7%

Other financials

Income statement

Revenue$790.0M+15.0%

Gross profit$362.0M-8.4%

Operating income-$100.0M-576%

Net income-$119.0M-1,090%

EPS (diluted)-$0.47-1,075%

Balance sheet

Cash & equivalents$10.0M0.0%

Total debt$61.0M—

Total equity$3.5B-0.7%

Total assets$4.3B—

Cash flow

Operating cash flow-$27.0M-147%

CapEx$167.0M+22.8%

Free cash flow-$194.0M-146%

Valuation

Market cap$3.86B—

Returns & leverage

Debt / equity0×—

Current ratio1.6×—

Where this comes from

Reported directly by MiniMed Group in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: MiniMed Group ’s 10-Q, filed April 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiniMed Group 's research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is MiniMed Group 's research and development expense?: MiniMed Group (MMED) reported research and development expense of $114M in Q1 2026.